Key result
Higher CHA2DS2-VASc-HS score linked to increased no-reflow risk in STEMI patients undergoing PPCI.
Why the study?
No-reflow phenomenon is a major drawback in STEMI patients treated with primary PCI, and its prediction remains clinically important.
Does the CHA2DS2-VASc-HS score predict the no-reflow phenomenon in patients with STEMI undergoing primary PCI?
Case-Control (n=100)
Does the CHA2DS2-VASc-HS score predict the no-reflow phenomenon in patients with STEMI undergoing primary PCI?
p-value: p=0.000
The CHA2DS2-VASc-HS score may serve as an effective tool for the early prediction of the no-reflow phenomenon in STEMI patients managed with primary PCI.
May aid no-reflow risk stratification in primary PCI for STEMI; hypothesis-generating and should not yet change practice.
Background: Current guidelines for acute ST-segment elevation myocardial infarction (STEMI) patients declared primary percutaneous coronary intervention (PPCI) as the mainstay reperfusion strategy. However, the no-reflow phenomenon(NRP) is a major drawback. The longer ischemia lasts, the more likely NRP is to occur causing more myocardial cells damage. Aim of the Work: to correlate between the CHA2DS2VAScHS score and NPR in patient presented with STEMI and treated with PPCI. Methods: Case-control study that included one hundred patients presented with STEMI and treated with PPCI. Patients were further divided into group(A) in which patients developed no-reflow (NR) after PPCI and group(B) in which patients achieved TIMI-III flow after PPCI. CHA2DS2VAScHS score was calculated for every patient. Results: The study showed an increase in no-reflow in patients with higher CHA2DS2VAScHS score and no-reflow in STEMI patients treated with PPCI (p-value:0.000). Conclusion: CHA2DS2VAScHS score is effective in the early prediction of NPR in patients with STEMI patients managed with PPCI.
No takes yet. Share an insight, caveat, or question.
Allam et al. (2023) conducted a case-control in ST-segment elevation myocardial infarction (STEMI) (n=100). CHA2DS2VAScHS score was evaluated on No-reflow phenomenon after primary percutaneous coronary intervention (p=0.000). A higher CHA2DS2VAScHS score was significantly associated with an increased risk of no-reflow in STEMI patients treated with primary percutaneous coronary intervention (p=0.000).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: